WEBVTT 00:00:00.000 --> 00:00:01.919 Welcome back to the deep dive where we take these 00:00:01.919 --> 00:00:06.360 massive stacks of data history and strategic 00:00:06.360 --> 00:00:09.640 decisions and we try to distill them into useful 00:00:09.640 --> 00:00:11.939 actionable knowledge you can absorb in a single 00:00:11.939 --> 00:00:15.679 sitting. Today we are attempting to solve a pretty 00:00:15.679 --> 00:00:18.359 major paradox in the business world. It's about 00:00:18.359 --> 00:00:22.370 the An immense scale of a corporation that, for 00:00:22.370 --> 00:00:24.750 all intents and purposes, actively avoids the 00:00:24.750 --> 00:00:27.170 spotlight. We are profiling Danaher Corporation. 00:00:27.670 --> 00:00:30.410 Exactly. A company whose technology underpins 00:00:30.410 --> 00:00:32.609 almost every major development in modern medicine, 00:00:32.829 --> 00:00:36.289 in diagnostics, and biotechnology. Yet if you 00:00:36.289 --> 00:00:38.049 go outside of Wall Street, almost no one even 00:00:38.049 --> 00:00:40.630 knows their name. And the scale is just astonishing. 00:00:40.890 --> 00:00:42.590 I mean, we're talking about a Fortune 500 company 00:00:42.590 --> 00:00:45.630 that in 2024 generated revenue of almost $24 00:00:45.630 --> 00:00:49.030 billion. $23 .9. to be exact. And they employ 00:00:49.030 --> 00:00:51.409 63 ,000 people across the globe. It's a crucial 00:00:51.409 --> 00:00:54.170 component of the S &P 500. They make the literal 00:00:54.170 --> 00:00:56.549 building blocks for vaccines, for cancer detection. 00:00:56.729 --> 00:00:58.990 But you'll never see a Danaher phone or a Danaher 00:00:58.990 --> 00:01:00.969 search engine. They are, you know, absolute masters 00:01:00.969 --> 00:01:03.130 of working behind the scenes. And that quiet 00:01:03.130 --> 00:01:05.969 power is really the core of our deep dive today. 00:01:06.450 --> 00:01:10.430 Our sources track the, well, the dizzying corporate 00:01:10.430 --> 00:01:13.250 evolution of Danaher, starting from its most 00:01:13.250 --> 00:01:16.040 humble beginnings. So our mission today is to 00:01:16.040 --> 00:01:18.400 unpack the successful strategy that allowed them 00:01:18.400 --> 00:01:22.420 to shift from this sprawling, diversified, industrial 00:01:22.420 --> 00:01:24.599 conglomerate. Right, making things like hand 00:01:24.599 --> 00:01:26.879 tools and pressure sensors. To a hyper -focused 00:01:26.879 --> 00:01:30.099 global giant in healthcare technology. We need 00:01:30.099 --> 00:01:32.079 to understand not just what they bought and sold, 00:01:32.200 --> 00:01:34.599 but how they did it. We're going to dive into 00:01:34.599 --> 00:01:36.980 the story of the founding brothers, Stephen Rails 00:01:36.980 --> 00:01:39.959 and Mitchell Rails, and really define the corporate 00:01:39.959 --> 00:01:43.040 engine they installed, the famous Danaher business 00:01:43.040 --> 00:01:45.439 system. That system really is the secret sauce, 00:01:45.579 --> 00:01:47.099 isn't it? It's what allowed them to constantly 00:01:47.099 --> 00:01:50.140 acquire, spin off and just ruthlessly refine 00:01:50.140 --> 00:01:52.219 their portfolio into the specialized machine 00:01:52.219 --> 00:01:54.659 that we see today. And finally, because they 00:01:54.659 --> 00:01:57.319 are now so focused on these vital life saving 00:01:57.319 --> 00:02:00.040 technologies, we have to examine the ethical 00:02:00.040 --> 00:02:02.500 implications of their success. Yeah, particularly 00:02:02.500 --> 00:02:04.900 the recent high profile controversies around 00:02:04.900 --> 00:02:07.099 the pricing and global accessibility of some 00:02:07.099 --> 00:02:09.699 of their most essential diagnostic tests. It's 00:02:09.699 --> 00:02:12.139 a crucial part of the story. OK, so let's begin 00:02:12.139 --> 00:02:14.340 with that initial snapshot of the modern company. 00:02:14.599 --> 00:02:17.460 It's an American health care giant headquartered 00:02:17.460 --> 00:02:20.379 in Washington, D .C., and it's focusing intensely 00:02:20.379 --> 00:02:24.680 on biotechnology, life sciences and diagnostics. 00:02:24.759 --> 00:02:26.939 And if you look at the 2024 revenue breakdown, 00:02:27.219 --> 00:02:30.240 that focus is crystal clear. Right. Diagnostics 00:02:30.240 --> 00:02:32.580 is the biggest piece of the pie. It is at 41 00:02:32.580 --> 00:02:35.020 percent of revenue. Then you've got life sciences 00:02:35.020 --> 00:02:38.060 making up 31 percent and biotechnology rounds 00:02:38.060 --> 00:02:40.740 out the portfolio at 28 percent. The mission 00:02:40.740 --> 00:02:43.379 is fully converged on high -tech healthcare delivery 00:02:43.379 --> 00:02:46.060 and manufacturing. It's just an incredibly specialized 00:02:46.060 --> 00:02:49.439 portfolio. It really is. And to truly appreciate 00:02:49.439 --> 00:02:52.340 the strategic clarity of the modern Danaher, 00:02:52.460 --> 00:02:55.129 you have to realize that 40 years ago... That 00:02:55.129 --> 00:02:57.430 focus was completely, totally absent. We have 00:02:57.430 --> 00:02:59.030 to go back to the very beginning. All right, 00:02:59.050 --> 00:03:01.030 let's unpack this history. And it starts in a 00:03:01.030 --> 00:03:04.110 place completely unrelated to gene therapy or, 00:03:04.150 --> 00:03:06.009 you know, anything we associate with them today. 00:03:06.430 --> 00:03:09.090 The company's true origins are in real estate 00:03:09.090 --> 00:03:11.050 investment. That's right. It was organized way 00:03:11.050 --> 00:03:14.990 back in 1969 as DMG Inc., which was a Massachusetts 00:03:14.990 --> 00:03:17.969 real estate investment trust. So like a REIT, 00:03:18.129 --> 00:03:20.849 what were they even doing? For nearly a decade, 00:03:21.030 --> 00:03:23.860 it was purely a financial entity. Eventually, 00:03:23.860 --> 00:03:27.080 it got reorganized in 1978 as Diversified Mortgage 00:03:27.080 --> 00:03:30.860 Investors, Inc., and it focused on these specialized 00:03:30.860 --> 00:03:33.259 projects like retirement home developments. So, 00:03:33.319 --> 00:03:36.639 a pretty sleepy business. Very slow, very traditional, 00:03:36.759 --> 00:03:39.460 and from what we can tell, struggling. Okay, 00:03:39.520 --> 00:03:41.719 so the narrative takes a really sharp turn in 00:03:41.719 --> 00:03:45.560 1983. This is with the entry of the Rails brothers, 00:03:45.919 --> 00:03:47.939 Stephen and Mitchell. And this wasn't a friendly 00:03:47.939 --> 00:03:50.169 investment. They came in very aggressively. They 00:03:50.169 --> 00:03:52.229 successfully waged what's called a proxy battle, 00:03:52.409 --> 00:03:55.449 ousted the existing management, and took control 00:03:55.449 --> 00:03:57.729 of what was, for all intents and purposes, a 00:03:57.729 --> 00:03:59.610 shell company. They saw a vehicle they could 00:03:59.610 --> 00:04:01.750 use. They immediately transformed that vehicle 00:04:01.750 --> 00:04:04.490 into an engine for external growth. They weren't 00:04:04.490 --> 00:04:06.409 interested in retirement homes. They were interested 00:04:06.409 --> 00:04:08.430 in buying and running industrial enterprises. 00:04:08.789 --> 00:04:12.110 And in 1984, they gave this new corporate vehicle 00:04:12.110 --> 00:04:16.430 its iconic name, Danaher. Correct. And this coincided 00:04:16.430 --> 00:04:18.910 with the company's reincorporation. under the 00:04:18.910 --> 00:04:21.829 Delaware General Corporation law, which is a 00:04:21.829 --> 00:04:25.370 very common move for corporations looking for 00:04:25.370 --> 00:04:28.610 favorable legal structures. But the name itself, 00:04:28.870 --> 00:04:31.810 that's such a fascinating touch of humanity and 00:04:31.810 --> 00:04:34.290 what is otherwise a pretty ruthless corporate 00:04:34.290 --> 00:04:36.949 story. It really is. It was named after Danaher 00:04:36.949 --> 00:04:39.550 Creek in western Montana. A place where the brothers 00:04:39.550 --> 00:04:41.370 were fly fishing and they conceived the whole 00:04:41.370 --> 00:04:44.189 idea for their new aggressive M &A enterprise. 00:04:44.569 --> 00:04:48.430 Exactly. It anchors this massive impersonal conglomerate 00:04:48.430 --> 00:04:51.370 to a very personal, quiet moment of reflection, 00:04:51.629 --> 00:04:54.110 which is a really interesting contrast. A sharp 00:04:54.110 --> 00:04:56.389 contrast, yeah. Because the strategy they immediately 00:04:56.389 --> 00:04:58.930 employed. was anything but quiet. It was aggressive, 00:04:59.129 --> 00:05:02.470 big game M &A hunting. You see this mentality 00:05:02.470 --> 00:05:04.649 immediately in 1985 when they went after the 00:05:04.649 --> 00:05:06.589 Scott Fetzer Company. And they launched a hostile 00:05:06.589 --> 00:05:09.949 bid, a $400 million hostile bid. Which was a 00:05:09.949 --> 00:05:12.889 lot of money back then. And this detail is critical 00:05:12.889 --> 00:05:16.389 because they lost that bid. And they didn't lose 00:05:16.389 --> 00:05:18.689 it to just some rival industrialist. No, they 00:05:18.689 --> 00:05:20.870 lost it to Warren Buffett's Berkshire Hathaway. 00:05:21.009 --> 00:05:24.769 To Buffett himself. And that loss serves as a 00:05:24.769 --> 00:05:27.610 really foundational moment. It tells us two things. 00:05:27.730 --> 00:05:30.509 First, that the Rails brothers were playing in 00:05:30.509 --> 00:05:32.649 the major leagues from day one. Absolutely. And 00:05:32.649 --> 00:05:35.509 second, that competing against someone like Buffett, 00:05:35.529 --> 00:05:38.810 who famously buys strong companies and just holds 00:05:38.810 --> 00:05:41.779 them indefinitely, requires a unique... discipline, 00:05:42.060 --> 00:05:44.180 strategic advantage. You can't just be another 00:05:44.180 --> 00:05:46.360 holding company. It must have signaled to them 00:05:46.360 --> 00:05:48.680 that they needed a superior operating system, 00:05:48.920 --> 00:05:51.939 something to let them extract value faster and 00:05:51.939 --> 00:05:53.939 more efficiently than anyone else. I think that's 00:05:53.939 --> 00:05:56.680 exactly right. And that strategic advantage soon 00:05:56.680 --> 00:05:58.899 crystallized, though it didn't yet have its famous 00:05:58.899 --> 00:06:00.980 name. And their aggression did pay off the following 00:06:00.980 --> 00:06:04.180 year in June of 1986. It did. With the successful 00:06:04.180 --> 00:06:06.920 hostile takeover of Chicago Pneumatic, they paid 00:06:06.920 --> 00:06:10.319 about $60 .8 million to acquire the final 32%. 00:06:10.800 --> 00:06:12.800 that they didn't already own. And Chicago Pneumatic 00:06:12.800 --> 00:06:15.100 was a pretty significant industrial prize at 00:06:15.100 --> 00:06:17.600 the time. It included Jacobs Manufacturing Co. 00:06:17.779 --> 00:06:21.139 and, importantly, Matco Tools. And this acquisition 00:06:21.139 --> 00:06:23.360 perfectly illustrates the nascent application 00:06:23.360 --> 00:06:26.300 of what would become the Danaher Business System, 00:06:26.379 --> 00:06:29.399 or DBS. Well, most acquirers buy a company, and 00:06:29.399 --> 00:06:32.019 then they run it as is, maybe make a few changes. 00:06:32.579 --> 00:06:35.720 Danaher bought Chicago Pneumatic. But less than 00:06:35.720 --> 00:06:39.360 a year later, in June of 87, they sold the main 00:06:39.360 --> 00:06:42.259 Chicago pneumatic business name. But they retained 00:06:42.259 --> 00:06:45.660 the key assets. They retained Jacobs Manufacturing, 00:06:45.740 --> 00:06:48.759 including the highly valuable Matco Tools division. 00:06:49.220 --> 00:06:51.959 They were buying companies to immediately optimize 00:06:51.959 --> 00:06:54.579 them and then harvest the most profitable parts. 00:06:55.240 --> 00:06:59.269 Jacobs was then renamed Matco Tools Corp. That 00:06:59.269 --> 00:07:01.370 sounds like a form of corporate arbitrage. You 00:07:01.370 --> 00:07:03.509 buy the whole thing, you strip out all the complexity, 00:07:03.589 --> 00:07:05.709 and you keep the crown jewels. That's a great 00:07:05.709 --> 00:07:07.689 way to put it. So they bought a famous tool company, 00:07:07.829 --> 00:07:09.850 sold the famous name, but kept the foundational 00:07:09.850 --> 00:07:11.790 assets. I mean, that's not really a business 00:07:11.790 --> 00:07:13.790 sale. It sounds more like extreme organizational 00:07:13.790 --> 00:07:16.470 efficiency. That's exactly the point. It's the 00:07:16.470 --> 00:07:18.649 application of the DBS principles before they 00:07:18.649 --> 00:07:21.720 were even formally named that. The Danaher business 00:07:21.720 --> 00:07:23.800 system is not just a set of financial rules. 00:07:24.000 --> 00:07:26.660 It is a culture of continuous improvement. Right, 00:07:26.720 --> 00:07:29.860 adapted from lean manufacturing principles. Often 00:07:29.860 --> 00:07:31.759 traced back to the Toyota production system, 00:07:31.879 --> 00:07:34.779 yes. It focuses intensely on the elimination 00:07:34.779 --> 00:07:38.300 of waste, rapid response, and constant refinement. 00:07:38.579 --> 00:07:40.600 So when they bought Chicago Pneumatic, they weren't 00:07:40.600 --> 00:07:42.879 just acquiring assets. They were acquiring a 00:07:42.879 --> 00:07:45.860 platform to apply this system. Precisely. And 00:07:45.860 --> 00:07:48.000 the assets that couldn't be efficiently improved 00:07:48.000 --> 00:07:50.560 under their system were just... Quickly spun 00:07:50.560 --> 00:07:53.000 off and sold, like the rest of the Jacobs divisions 00:07:53.000 --> 00:07:55.980 they divested in 1991. And that really establishes 00:07:55.980 --> 00:07:58.120 their initial industrial footprint. It moves 00:07:58.120 --> 00:08:00.540 them decisively away from real estate and into 00:08:00.540 --> 00:08:02.720 instrumentation and industrial tools. It does. 00:08:02.879 --> 00:08:05.360 By 1986, for instance, they had already added 00:08:05.360 --> 00:08:08.019 a company called Qualitrol, which gave them specialized 00:08:08.019 --> 00:08:10.399 instruments like Gilbarco -Viderud underground 00:08:10.399 --> 00:08:13.300 fuel storage sensors and Dynapar motion sensors. 00:08:13.639 --> 00:08:16.319 So by 1990, Danaher had successfully transitioned 00:08:16.319 --> 00:08:19.379 from a sleepy investment trust to a classic diversified... 00:08:19.370 --> 00:08:21.709 industrial conglomerate. But one with a crucial 00:08:21.709 --> 00:08:24.550 difference. It was operating under this highly 00:08:24.550 --> 00:08:27.089 disciplined, constantly self -improving operational 00:08:27.089 --> 00:08:31.189 system, DBS, which prioritized efficiency over 00:08:31.189 --> 00:08:34.529 just sheer size. And that system was about to 00:08:34.529 --> 00:08:37.809 guide them through a massive, multi -decade pivot. 00:08:38.070 --> 00:08:40.549 Okay, so moving to the 1990s, Danaher continued 00:08:40.549 --> 00:08:43.090 to solidify this position as a major player in 00:08:43.090 --> 00:08:46.000 the tool and industrial sector. They're building 00:08:46.000 --> 00:08:48.980 this empire of physical products while at the 00:08:48.980 --> 00:08:51.580 same time refining their application of DBS. 00:08:51.860 --> 00:08:54.600 The 1990s were all about cementing market dominance 00:08:54.600 --> 00:08:57.259 through scale in their core industrial segments. 00:08:57.600 --> 00:09:00.799 The acquisition of Isco Hand Tools Inc. in 1990 00:09:00.799 --> 00:09:03.559 was huge. Why was that one so important? because 00:09:03.559 --> 00:09:05.620 it led to Danaher becoming the exclusive hand 00:09:05.620 --> 00:09:08.159 tool supplier for Sears. Wow. At the time, that 00:09:08.159 --> 00:09:10.200 was a massive channel. It's a powerful commercial 00:09:10.200 --> 00:09:12.299 validation of their ability to manage a huge 00:09:12.299 --> 00:09:14.820 supply chain efficiently under the DBS model. 00:09:15.019 --> 00:09:17.440 And they just kept consolidating. In 1994, they 00:09:17.440 --> 00:09:19.620 acquired Armstrong Tools. Right. Adding established 00:09:19.620 --> 00:09:21.600 brand names like Armstrong and Allen to their 00:09:21.600 --> 00:09:23.960 portfolio, further cornering the U .S. industrial 00:09:23.960 --> 00:09:26.240 and consumer tool market. And their ambitions 00:09:26.240 --> 00:09:28.700 were growing beyond North America. They were. 00:09:28.860 --> 00:09:31.620 In 1995, they completed their first international 00:09:31.620 --> 00:09:34.519 acquisition, a German company called Hengstler 00:09:34.519 --> 00:09:37.539 GmbH. And what did they make? They were a manufacturer 00:09:37.539 --> 00:09:39.980 of high precision rotational sensors, counters 00:09:39.980 --> 00:09:42.639 and relays. So this shows they were already seeking 00:09:42.639 --> 00:09:44.899 out advanced manufacturing and high tolerance 00:09:44.899 --> 00:09:47.440 sensing technology wherever they could find it 00:09:47.440 --> 00:09:49.580 globally. OK, so here is where it gets really 00:09:49.580 --> 00:09:52.059 interesting for me, because the strategic pivot 00:09:52.059 --> 00:09:55.210 starts right at the end of the century. After 00:09:55.210 --> 00:09:57.950 building this massive tool and sensor empire 00:09:57.950 --> 00:10:03.230 in 1999, Danaher acquires Hatch Company for $325 00:10:03.230 --> 00:10:07.149 million. And Hatch specializes in water and wastewater 00:10:07.149 --> 00:10:10.659 analytics. This is a subtle yet profound shift. 00:10:10.860 --> 00:10:12.799 It feels like it comes out of left fuel. It does, 00:10:12.899 --> 00:10:15.340 but it's the ultimate DBS -driven move. Think 00:10:15.340 --> 00:10:17.299 about it. They shift from making the physical 00:10:17.299 --> 00:10:19.539 tools for industrial work, the wrenches and the 00:10:19.539 --> 00:10:21.960 compressors, to making the scientific instruments 00:10:21.960 --> 00:10:24.440 used for high -precision measurement and chemical 00:10:24.440 --> 00:10:27.269 analysis. That's a huge leap in complexity. A 00:10:27.269 --> 00:10:30.129 massive leap. Water quality is a highly regulated 00:10:30.129 --> 00:10:32.929 field. It requires complex instrumentation, chemical 00:10:32.929 --> 00:10:35.870 reagents. This move took Danaher from simple 00:10:35.870 --> 00:10:39.129 industrial manufacturing into the complex, regulated 00:10:39.129 --> 00:10:41.789 analytical sectors. And the change in focus was 00:10:41.789 --> 00:10:44.730 reinforced at the highest level. In 2000, H. 00:10:44.730 --> 00:10:47.429 Lawrence Culp Jr., a longtime company leader, 00:10:47.570 --> 00:10:51.009 was named CEO. And he took the reins and immediately 00:10:51.009 --> 00:10:53.509 set the stage for aggressively pursuing this 00:10:53.509 --> 00:10:58.000 new analytical future. just opened the floodgates. 00:10:58.120 --> 00:11:00.340 Once they proved they could successfully acquire 00:11:00.340 --> 00:11:03.600 and integrate a complex, regulated, analytical 00:11:03.600 --> 00:11:06.480 company using DBS principles, they aggressively 00:11:06.480 --> 00:11:10.019 started piling on medical and scientific instrumentation. 00:11:10.220 --> 00:11:12.220 That's right. You see that diversification to 00:11:12.220 --> 00:11:14.139 life sciences and diagnostics beginning with 00:11:14.139 --> 00:11:16.720 the dental industry. They acquired Gendex Dental 00:11:16.720 --> 00:11:20.639 Imaging around 2003 or 2004. Which began a significant 00:11:20.639 --> 00:11:23.539 dental portfolio that, as we'll discuss, they 00:11:23.539 --> 00:11:25.200 would later decide wasn't core enough for them. 00:11:25.320 --> 00:11:28.340 Right. Then in 2004, they reinforced that initial 00:11:28.340 --> 00:11:30.820 analytical investment with Trojan Technologies, 00:11:31.019 --> 00:11:33.539 which is an environmental engineering firm focused 00:11:33.539 --> 00:11:36.159 on water disinfection. So still in that water 00:11:36.159 --> 00:11:37.960 space. But the key leap, the really big one, 00:11:38.000 --> 00:11:41.100 came in 2005. The acquisition of Leica Microsystems. 00:11:41.100 --> 00:11:43.500 And Leica is a huge name in science. They produce 00:11:43.500 --> 00:11:46.340 equipment for microscopic imaging, measurement 00:11:46.340 --> 00:11:49.919 analysis. things that are essential for biotechnology 00:11:49.919 --> 00:11:52.799 and medicine. This is a major leap in technical 00:11:52.799 --> 00:11:55.740 sophistication. You're moving beyond basic sensors 00:11:55.740 --> 00:11:58.100 into the advanced high -resolution optical and 00:11:58.100 --> 00:12:00.759 imaging tools that are essential for any research 00:12:00.759 --> 00:12:03.279 or pathology lab. And this systematic assembly 00:12:03.279 --> 00:12:05.659 of the, you know, the modern scientific kit just 00:12:05.659 --> 00:12:09.500 continued. In 2007, they spent $520 million on 00:12:09.500 --> 00:12:12.139 a company called Vision Systems. Vision Systems 00:12:12.139 --> 00:12:15.320 made automated instruments, antibodies and biochemical 00:12:15.320 --> 00:12:18.019 regions used for biopsy based detection of cancer 00:12:18.019 --> 00:12:20.679 and infectious diseases. That is pure high margin 00:12:20.679 --> 00:12:23.019 diagnostics. And Danaher was not afraid to put 00:12:23.019 --> 00:12:25.399 immense capital behind this new high tech focus. 00:12:25.659 --> 00:12:28.460 This whole era is really defined by the two largest 00:12:28.460 --> 00:12:30.600 technology bets they had made up to that point. 00:12:30.960 --> 00:12:34.000 The first, in November of 2007, was the purchase 00:12:34.000 --> 00:12:37.740 of Tektronix for $2 .85 billion. Their largest 00:12:37.740 --> 00:12:40.399 acquisition ever at the time. By far. And it 00:12:40.399 --> 00:12:42.759 was a massive commitment to high -tech instrumentation 00:12:42.759 --> 00:12:45.019 and electronic measurement. It proved they were 00:12:45.019 --> 00:12:46.860 deadly serious about moving up the technology 00:12:46.860 --> 00:12:49.500 value chain into complex electronics. And the 00:12:49.500 --> 00:12:52.899 second massive bet was a true analytical powerhouse. 00:12:53.100 --> 00:12:57.220 A .B. S -C -I -E -X. Acquired between 2009 and 00:12:57.220 --> 00:13:00.960 2010 for a total of $1 .1 billion. This was done 00:13:00.960 --> 00:13:03.340 in two stages, first buying a 50 % interest from 00:13:03.340 --> 00:13:05.480 a company called MDS, and then the remaining 00:13:05.480 --> 00:13:08.740 50 % from Life Technologies. Okay, so A -B -S 00:13:08.740 --> 00:13:11.139 -C -I -E -X is crucial. Why? What do they do 00:13:11.139 --> 00:13:13.139 that's so important? They are massive in mass 00:13:13.139 --> 00:13:15.279 spectrometry and chromatography. Okay, so for 00:13:15.279 --> 00:13:16.919 anyone listening who isn't a chemist, can you 00:13:16.919 --> 00:13:19.080 contextualize that for us? Absolutely. Think 00:13:19.080 --> 00:13:21.019 of mass spectrometry as the forensic tool of 00:13:21.019 --> 00:13:23.399 chemistry. It allows scientists to weigh molecules 00:13:23.399 --> 00:13:25.919 with incredible precision. So it's vital for 00:13:25.919 --> 00:13:28.379 what? Drug quality. Exactly. For ensuring drug 00:13:28.379 --> 00:13:31.340 quality, identifying unknown contaminants, validating 00:13:31.340 --> 00:13:34.360 complex biological samples. And chromatography 00:13:34.360 --> 00:13:36.460 is the separation method that prepares those 00:13:36.460 --> 00:13:40.139 samples to be analyzed. So by acquiring ABSCIEX, 00:13:40.379 --> 00:13:42.779 Danaher gained control over the fundamental instruments 00:13:42.779 --> 00:13:45.720 required for modern drug discovery, for pharmaceutical 00:13:45.720 --> 00:13:48.500 manufacturing quality control, and for advanced 00:13:48.500 --> 00:13:52.120 toxicology. That's it. So by 2010, the company 00:13:52.120 --> 00:13:54.440 had fully shed its primary industrial identity. 00:13:54.889 --> 00:13:57.830 Its largest, most expensive assets were not wrenches 00:13:57.830 --> 00:14:00.470 or compressors anymore. They were the sophisticated 00:14:00.470 --> 00:14:03.389 scientific and medical instrumentation powering 00:14:03.389 --> 00:14:06.330 global laboratories. The foundation for the current 00:14:06.330 --> 00:14:08.750 healthcare giant was fully laid, built on these 00:14:08.750 --> 00:14:11.009 analytical platforms they could integrate using 00:14:11.009 --> 00:14:14.590 DBS. The decade starting in 2011. is where the 00:14:14.590 --> 00:14:17.129 strategy shifts from just acquiring diverse analytical 00:14:17.129 --> 00:14:20.009 businesses to acquiring massive scale within 00:14:20.009 --> 00:14:22.750 a very narrow focused vertical. The acquisitions 00:14:22.750 --> 00:14:24.970 get dramatically bigger, but the focus narrows 00:14:24.970 --> 00:14:27.590 like a laser beam onto health care. And the 2011 00:14:27.590 --> 00:14:30.710 acquisition of Beckman Coulter immediately accelerates 00:14:30.710 --> 00:14:32.830 this shift. They bought it and then quickly divided 00:14:32.830 --> 00:14:35.149 it into diagnostics and life sciences segments. 00:14:35.330 --> 00:14:37.889 And that move instantly reinforced the three 00:14:37.889 --> 00:14:41.009 core divisions, diagnostics, life sciences, and 00:14:41.009 --> 00:14:43.710 biopharma, that define Danaher today. It did. 00:14:44.490 --> 00:14:47.769 But the true genius of Danaher's later strategy... 00:14:47.799 --> 00:14:50.299 and really the combination of DBS, is defined 00:14:50.299 --> 00:14:52.879 as much by what they sold. Right. They realized 00:14:52.879 --> 00:14:55.899 that to make the truly massive, multi -billion 00:14:55.899 --> 00:14:58.159 dollar strategic bets they needed for biopharma 00:14:58.159 --> 00:15:01.379 dominance, they had to ruthlessly shed every 00:15:01.379 --> 00:15:04.460 single asset that wasn't top tier in terms of 00:15:04.460 --> 00:15:07.299 margin, growth potential, or strategic fit. And 00:15:07.299 --> 00:15:09.539 that discipline divestment is what created the 00:15:09.539 --> 00:15:12.399 organizational clarity, and I imagine the immense 00:15:12.399 --> 00:15:14.720 capital needed for the blockbusters that followed. 00:15:14.940 --> 00:15:16.740 That's it. But that makes sense financially. 00:15:17.100 --> 00:15:19.159 But to what extent did that constant buying, 00:15:20.200 --> 00:15:22.639 integrating, improving, and then selling off 00:15:22.639 --> 00:15:24.960 assets they'd owned for decades, to what extent 00:15:24.960 --> 00:15:27.700 did that risk organizational paralysis or maybe 00:15:27.700 --> 00:15:30.700 the loss of a coherent corporate identity? That's 00:15:30.700 --> 00:15:33.580 a great question. And that's where DBS. really 00:15:33.580 --> 00:15:35.919 proves its worth as a cultural system, not just 00:15:35.919 --> 00:15:38.779 a process. DDS provides a standardized language 00:15:38.779 --> 00:15:41.340 and a toolkit for operational improvement that 00:15:41.340 --> 00:15:43.600 applies whether you're making a hand tool or 00:15:43.600 --> 00:15:45.679 an mRNA component. So it's the common thread. 00:15:45.840 --> 00:15:48.830 It's the common thread. It ensures that the core 00:15:48.830 --> 00:15:51.590 culture of efficiency and improvement remains, 00:15:51.909 --> 00:15:55.029 even when the assets themselves change dramatically. 00:15:55.330 --> 00:15:57.509 They are constantly optimizing the organization, 00:15:57.809 --> 00:16:00.269 which is why they can handle these massive spinoffs 00:16:00.269 --> 00:16:02.629 without collapsing. Let's detail these major 00:16:02.629 --> 00:16:05.029 spinoffs because they tell such a powerful story 00:16:05.029 --> 00:16:08.129 of strategic commitment and culling. OK, so in 00:16:08.129 --> 00:16:10.970 February 2013, they sold off one of the key pillars 00:16:10.970 --> 00:16:13.730 of their industrial past, the joint venture Apex 00:16:13.730 --> 00:16:17.529 Tool Group, to Bain Capital for $1 .6 billion. 00:16:18.450 --> 00:16:20.629 That's a serious chunk of their manufacturing 00:16:20.629 --> 00:16:23.389 legacy just gone. But the biggest move came in 00:16:23.389 --> 00:16:26.549 June 2016 with the massive corporate spinoff 00:16:26.549 --> 00:16:28.610 of Fortiv. This was a monumental shedding of 00:16:28.610 --> 00:16:31.309 assets. Fortiv took with it huge pieces of the 00:16:31.309 --> 00:16:33.429 original industrial and instrumentation businesses. 00:16:33.690 --> 00:16:35.789 Including Matco Tools, right, which was one of 00:16:35.789 --> 00:16:37.769 the crown jewels. they had kept from that Chicago 00:16:37.769 --> 00:16:40.190 pneumatic deal back in the 80s. Exactly. Matco 00:16:40.190 --> 00:16:43.529 and AMM CO codes both gone to Ford. And they 00:16:43.529 --> 00:16:45.470 just continued to strip away complexity. They 00:16:45.470 --> 00:16:47.590 had built up a substantial dental business over 00:16:47.590 --> 00:16:50.070 the years, including Nobel Biocare, which they 00:16:50.070 --> 00:16:53.549 acquired for $2 .2 billion in 2014. But by December 00:16:53.549 --> 00:16:56.990 2019, they spun the entire dental segment off 00:16:56.990 --> 00:16:59.960 into Invista Holdings Corporation. So even though 00:16:59.960 --> 00:17:02.399 dental is high margin, it just didn't fit the 00:17:02.399 --> 00:17:05.460 narrow scientific bioprocessing focus they were 00:17:05.460 --> 00:17:08.180 cultivating? It didn't. And the final piece of 00:17:08.180 --> 00:17:11.119 this strategic culling came recently, in September 00:17:11.119 --> 00:17:14.339 of 2023, with the spinoff of the environmental 00:17:14.339 --> 00:17:16.779 and applied solutions segment into a new public 00:17:16.779 --> 00:17:19.299 company called Viralto. And that included some 00:17:19.299 --> 00:17:22.200 highly recognizable, important names that signaled 00:17:22.200 --> 00:17:24.819 their pivot two decades earlier. Like Hatch Company. 00:17:25.019 --> 00:17:28.339 Hatch. Chemtreat, Trojan Technologies, and even 00:17:28.339 --> 00:17:30.960 creative tech brands like Pantone, Esco, and 00:17:30.960 --> 00:17:33.299 Videojet. They literally stripped away every 00:17:33.299 --> 00:17:36.000 single asset that wasn't pure life sciences or 00:17:36.000 --> 00:17:38.700 diagnostics. It's a breathtaking act of corporate 00:17:38.700 --> 00:17:40.579 refinement. It really demonstrates that they 00:17:40.579 --> 00:17:43.019 are not interested in being a general conglomerate. 00:17:43.059 --> 00:17:45.599 They want monopolistic influence within a handful 00:17:45.599 --> 00:17:49.339 of hyper -specific, high -growth, regulated scientific 00:17:49.339 --> 00:17:51.759 markets. And once that focus was established, 00:17:52.079 --> 00:17:54.400 the biopharma blockbusters started rolling in, 00:17:54.440 --> 00:17:56.319 cementing their leadership in the life sciences 00:17:56.319 --> 00:17:58.839 manufacturing supply chain. The scale of these 00:17:58.839 --> 00:18:01.880 deals is just staggering. In August 2015, they 00:18:01.880 --> 00:18:04.960 acquired Paul Corporation for $13 .8 billion. 00:18:05.339 --> 00:18:07.559 And Paul is absolutely critical for filtration 00:18:07.559 --> 00:18:10.039 and fluid management in pharmaceutical and biologic 00:18:10.039 --> 00:18:12.220 manufacturing. It's essential. The very next 00:18:12.220 --> 00:18:15.759 year, 2016, they acquired Cepheid for $4 billion. 00:18:16.220 --> 00:18:19.299 Which was a crucial move to expand their molecular 00:18:19.299 --> 00:18:22.700 diagnostics, giving them control over that unique 00:18:22.700 --> 00:18:26.579 rapid testing cartridge. technology, which will 00:18:26.579 --> 00:18:28.579 feature heavily in our discussion of the controversy 00:18:28.579 --> 00:18:32.119 later on. Okay. Then in 2018, they acquired Integrated 00:18:32.119 --> 00:18:36.640 DNA Technologies, IDT, for $1 .9 billion. And 00:18:36.640 --> 00:18:39.440 this acquisition was strategic gold. IDT manufactured 00:18:39.440 --> 00:18:41.980 something called oligonucleotides and synthetic 00:18:41.980 --> 00:18:45.180 DNA. So for the listener, what are oligonucleotides? 00:18:45.319 --> 00:18:47.640 They're small strands of synthetic DNA or RNA 00:18:47.640 --> 00:18:50.019 that act as primers or instructions. They are 00:18:50.019 --> 00:18:51.940 the essential genetic components you need to 00:18:51.940 --> 00:18:54.440 start virtually any modern molecular test or 00:18:54.440 --> 00:18:56.660 gene sequencing process. So this explains their 00:18:56.660 --> 00:18:58.599 immediate relevance during the 2020 pandemic. 00:18:59.140 --> 00:19:02.299 Absolutely. IDT was manufacturing key components 00:19:02.299 --> 00:19:05.140 needed for almost all of the COVID -19 testing 00:19:05.140 --> 00:19:08.490 protocols. Danaher positioned itself as the supplier 00:19:08.490 --> 00:19:10.990 for the suppliers. But the single biggest strategic 00:19:10.990 --> 00:19:13.950 move was the acquisition of the biopharma business 00:19:13.950 --> 00:19:17.710 of General Electric in March of 2020. For a staggering 00:19:17.710 --> 00:19:22.890 $21 .4 billion. $21 .4 billion. And this deal, 00:19:22.930 --> 00:19:25.450 which they subsequently rebranded as Sativa. 00:19:26.009 --> 00:19:28.250 instantly made Danaher the largest player in 00:19:28.250 --> 00:19:30.289 the biomanufacturing supply chain. So what does 00:19:30.289 --> 00:19:32.750 Sativa do? It provides the essential technologies 00:19:32.750 --> 00:19:35.690 and services, so consumables, instruments, software, 00:19:35.930 --> 00:19:37.910 that are needed for the development and manufacture 00:19:37.910 --> 00:19:41.210 of vaccines, diagnostics, and therapeutics. To 00:19:41.210 --> 00:19:43.650 put it simply... If a pharmaceutical company 00:19:43.650 --> 00:19:46.529 is making a monoclonal antibody drug or a vaccine, 00:19:46.769 --> 00:19:49.609 they must use components supplied by Sativa or 00:19:49.609 --> 00:19:51.789 Paul. That's the level of control they've achieved. 00:19:52.009 --> 00:19:54.549 It's incredible. And the name Sativa really reflects 00:19:54.549 --> 00:19:57.269 that new focus. It does. Cito meaning cell in 00:19:57.269 --> 00:20:00.849 Greek and Eva, a Latin suffix meaning doing or 00:20:00.849 --> 00:20:03.170 capable of. The name literally means capable 00:20:03.170 --> 00:20:05.250 of working with cells. Now, it's important to 00:20:05.250 --> 00:20:07.750 note the regulatory steps involved here, right? 00:20:07.769 --> 00:20:10.569 This deal was so large and potentially monopolistic. 00:20:10.569 --> 00:20:12.420 Right. The federal trade. Commission mandated 00:20:12.420 --> 00:20:14.960 that Danaher divest certain overlapping assets, 00:20:15.240 --> 00:20:17.779 specifically things like chromatography hardware, 00:20:18.079 --> 00:20:20.960 resins, microcarriers. They had to sell them 00:20:20.960 --> 00:20:24.640 to Sartorius AG for about $825 million. Which 00:20:24.640 --> 00:20:26.980 is really a regulatory nod to the immense power 00:20:26.980 --> 00:20:29.839 they were consolidating. It is. And the momentum 00:20:29.839 --> 00:20:33.430 hasn't slowed. In August 2021, Danaher acquired 00:20:33.430 --> 00:20:37.369 Aldevron for $9 .6 billion. And Aldevron is laser 00:20:37.369 --> 00:20:39.990 -focused on producing highly specialized GMP 00:20:39.990 --> 00:20:43.890 -grade plasmid DNA, mRNA, and proteins used specifically 00:20:43.890 --> 00:20:47.430 in mRNA vaccines and advanced gene and cell therapies. 00:20:47.769 --> 00:20:49.269 They are positioning themselves to capitalize 00:20:49.269 --> 00:20:51.170 on the next few decades of biotech innovation. 00:20:51.470 --> 00:20:53.849 It's very forward -looking. And then in May 2023, 00:20:54.230 --> 00:20:57.329 they merged Paul Corporation with Sativa. Right, 00:20:57.369 --> 00:20:59.509 streamlining their massive bioprocessing and 00:20:59.509 --> 00:21:02.130 filtration unit. into a singular integrated biotechnology 00:21:02.130 --> 00:21:05.670 group. And they closed the $5 .7 billion acquisition 00:21:05.670 --> 00:21:08.569 of Abcam in December 2023, further bolstering 00:21:08.569 --> 00:21:10.490 their antibody and region offerings for the research 00:21:10.490 --> 00:21:13.029 segment. Speaking of recent developments, 2024 00:21:13.029 --> 00:21:16.299 shows no sign of slowing down. Not at all. In 00:21:16.299 --> 00:21:19.319 June, Danaher's Cepheid unit received FDA approval 00:21:19.319 --> 00:21:22.960 for a rapid hepatitis C RNA test. And the key 00:21:22.960 --> 00:21:25.859 technical feature here is its ability to detect 00:21:25.859 --> 00:21:28.559 the virus using just a fingertip blood sample 00:21:28.559 --> 00:21:31.519 in less than an hour. Which completely bypasses 00:21:31.519 --> 00:21:33.740 the traditional requirement of sending a sample 00:21:33.740 --> 00:21:36.759 to a centralized lab. This decentralizes and 00:21:36.759 --> 00:21:39.279 speeds up critical diagnostics. It's a huge step. 00:21:39.440 --> 00:21:42.400 And just recently, in August 2024, they acquired 00:21:42.400 --> 00:21:45.490 Genadata. A company that reinforces their analytical 00:21:45.490 --> 00:21:47.789 and software capabilities within the life sciences 00:21:47.789 --> 00:21:50.849 platform, ensuring they stay current with bioinformatics 00:21:50.849 --> 00:21:53.809 and drug discovery data processing. It's just 00:21:53.809 --> 00:21:56.369 this relentless, continuous cycle of buying and 00:21:56.369 --> 00:21:58.970 optimizing highly specialized scientific platforms, 00:21:59.210 --> 00:22:02.029 all driven by the DBS playbook. So we've tracked 00:22:02.029 --> 00:22:04.450 this journey from, what, retirement homes and 00:22:04.450 --> 00:22:06.690 ratchet wrenches, through this strategic culling 00:22:06.690 --> 00:22:09.710 of Viralto and Fortiv, and finally to mRNA manufacturing. 00:22:10.109 --> 00:22:12.410 Let's look at what the focused post -Viralto 00:22:12.410 --> 00:22:19.059 data... The modern configuration is defined by 00:22:19.059 --> 00:22:22.599 extreme focus on three high -tech, high -growth 00:22:22.599 --> 00:22:24.880 verticals within the healthcare industry. And 00:22:24.880 --> 00:22:27.119 each of them operates with a high degree of integration 00:22:27.119 --> 00:22:30.700 under the umbrella of DBS efficiency. OK, so 00:22:30.700 --> 00:22:33.259 first up is diagnostics. It's the largest segment 00:22:33.259 --> 00:22:37.140 at 41 percent of 2024 revenue. And this division 00:22:37.140 --> 00:22:39.859 provides the instruments, the consumables, software 00:22:39.859 --> 00:22:42.339 and services used by clinical labs and hospitals 00:22:42.339 --> 00:22:45.880 globally to rapidly and accurately diagnose diseases. 00:22:46.279 --> 00:22:48.380 So think of them as the like the centralized 00:22:48.380 --> 00:22:50.940 industrial plumbing of the diagnostic world. 00:22:51.180 --> 00:22:53.420 What's a good way to put it? Second is life sciences. 00:22:53.799 --> 00:22:56.539 representing 31 % of revenue. This group is centered 00:22:56.539 --> 00:22:58.980 on discovery and research. So these are the tools 00:22:58.980 --> 00:23:01.200 used before the drug is ready for manufacturing. 00:23:01.500 --> 00:23:03.799 Exactly. They develop products used to identify 00:23:03.799 --> 00:23:06.180 the causes of disease, research new therapies, 00:23:06.440 --> 00:23:08.740 and conduct testing for new drugs, vaccines, 00:23:08.940 --> 00:23:11.900 and gene editing technologies. And finally, biotechnology, 00:23:12.180 --> 00:23:14.940 making up 28 % of revenue. And this division 00:23:14.940 --> 00:23:16.900 develops products specifically focused on the 00:23:16.900 --> 00:23:19.319 actual development and manufacturing of therapeutics. 00:23:19.690 --> 00:23:22.250 This is where the heavy -duty bioprocessing equipment, 00:23:22.509 --> 00:23:25.029 the filters, and the complex manufacturing solutions 00:23:25.029 --> 00:23:27.490 live. What's essential to understand here is 00:23:27.490 --> 00:23:29.349 the synergy, right? Danaher doesn't just own 00:23:29.349 --> 00:23:31.450 three separate divisions. They own the supply 00:23:31.450 --> 00:23:34.190 chain that links basic research. In life sciences. 00:23:34.430 --> 00:23:36.710 To high -volume manufacturing and biotechnology. 00:23:36.730 --> 00:23:39.670 And then finally to patient care and diagnostics. 00:23:39.670 --> 00:23:41.769 It's a fully integrated pipeline. So let's delve 00:23:41.769 --> 00:23:43.990 into the specific subsidiaries within these groups 00:23:43.990 --> 00:23:46.250 to illustrate that immense specialized reach. 00:23:46.670 --> 00:23:49.130 In the biotechnology group, the primary assets 00:23:49.130 --> 00:23:52.390 are Sativa and Paul Corporation, which, as you 00:23:52.390 --> 00:23:55.490 said, merged in May of 2023. And this merger 00:23:55.490 --> 00:23:58.289 consolidated control over the entire bioprocessing 00:23:58.289 --> 00:24:01.170 workflow. Sativa and Paul are responsible for 00:24:01.170 --> 00:24:04.509 manufacturing the disposable, single -use bioreactors, 00:24:04.529 --> 00:24:06.869 the spectralized tubing, and the high -efficiency 00:24:06.869 --> 00:24:09.849 filtration systems that are just non -negotiable 00:24:09.849 --> 00:24:12.390 for producing most modern biological drugs and 00:24:12.390 --> 00:24:15.140 vaccines. How big is that combined group? They 00:24:15.140 --> 00:24:18.359 employ over 16 ,000 associates and are absolute 00:24:18.359 --> 00:24:22.000 global innovation leaders in separation and bioprocessing 00:24:22.000 --> 00:24:24.720 technologies. Okay, so moving to diagnostics. 00:24:24.779 --> 00:24:28.299 This includes several major recognizable players. 00:24:28.579 --> 00:24:31.400 We have Beckman -Coulter Diagnostics. Which is 00:24:31.400 --> 00:24:33.720 central to clinical lab automation. They provide 00:24:33.720 --> 00:24:35.819 the large centralized testing machines you'd 00:24:35.819 --> 00:24:38.119 find in most major hospitals. And complementing 00:24:38.119 --> 00:24:40.099 that are more specialized units like Cepheid. 00:24:40.259 --> 00:24:42.700 Known for its molecular diagnostics, the rapid 00:24:42.700 --> 00:24:44.579 response diagnostic unit we discussed earlier. 00:24:44.799 --> 00:24:47.660 Then there is Leica Biosystems, which focuses 00:24:47.660 --> 00:24:50.200 on instruments and reagents crucial for pathology 00:24:50.200 --> 00:24:53.160 and cancer detection. And Radiometer, which deals 00:24:53.160 --> 00:24:55.920 with acute care diagnostics, often right at the 00:24:55.920 --> 00:24:58.160 bedside. So it's like having a general practitioner 00:24:58.160 --> 00:25:00.539 and a specialist within the same family. Beckman 00:25:00.539 --> 00:25:02.839 Coulter handles the high volume general. blood 00:25:02.839 --> 00:25:05.980 work. And Cepheid handles the immediate, high 00:25:05.980 --> 00:25:08.579 -specificity molecular testing for pathogens 00:25:08.579 --> 00:25:11.859 like TB or COVID. Got it. Then there is the massive 00:25:11.859 --> 00:25:14.819 life sciences segment, the 31 % dedicated to 00:25:14.819 --> 00:25:17.099 research and discovery. And this is a highly 00:25:17.099 --> 00:25:20.559 varied and rich group that really fuels the future 00:25:20.559 --> 00:25:24.160 pipeline. It includes the recently acquired Abcam, 00:25:24.400 --> 00:25:27.000 a major supplier of highly specific antibodies 00:25:27.000 --> 00:25:30.210 and reagents critical for research. It also includes 00:25:30.210 --> 00:25:32.970 Beckman Culture Life Sciences, focusing on research 00:25:32.970 --> 00:25:35.849 instrumentation and integrated DNA technologies, 00:25:36.150 --> 00:25:39.109 IDT. Providing those essential genetic primers 00:25:39.109 --> 00:25:41.950 for molecular research. And we also find Leica 00:25:41.950 --> 00:25:44.029 Microsystems here. Supplying the microscopic 00:25:44.029 --> 00:25:47.450 imaging tools, molecular devices, offering analytical 00:25:47.450 --> 00:25:49.710 instrumentation. The part of Paul Corporation 00:25:49.710 --> 00:25:52.089 that serves non -biotech life science filtration 00:25:52.089 --> 00:25:57.069 needs. And of course, SCIEX, offering those incredibly 00:25:57.069 --> 00:25:59.710 advanced mass spectrometry. technology is crucial 00:25:59.710 --> 00:26:02.430 for chemical validation and compound identification. 00:26:02.849 --> 00:26:05.289 What stands out to me is that Danaher has positioned 00:26:05.289 --> 00:26:07.430 itself at the point of greatest necessity. They 00:26:07.430 --> 00:26:09.329 don't make the drug itself, but they provide 00:26:09.329 --> 00:26:11.670 the irreplaceable infrastructure. The instruments, 00:26:11.849 --> 00:26:14.589 the reagents, the analysis software, the critical 00:26:14.589 --> 00:26:16.450 manufacturing components. That the drug companies 00:26:16.450 --> 00:26:19.210 and diagnostic labs absolutely must have to operate. 00:26:19.309 --> 00:26:20.950 They are selling the building blocks of science 00:26:20.950 --> 00:26:23.509 itself. Which brings us directly to the critical 00:26:23.509 --> 00:26:26.140 lens of accountability. Yeah, this transition 00:26:26.140 --> 00:26:28.839 is vital. When a company gains this level of 00:26:28.839 --> 00:26:31.420 focus, indispensable power over technologies 00:26:31.420 --> 00:26:34.339 that literally save lives, the success story 00:26:34.339 --> 00:26:37.180 inevitably morphs into a conversation about ethical 00:26:37.180 --> 00:26:40.299 responsibility and accessibility. And the primary 00:26:40.299 --> 00:26:42.480 ethical dimension we need to examine focuses 00:26:42.480 --> 00:26:46.039 squarely on Danher's diagnostic subsidiary, Cepheid. 00:26:46.349 --> 00:26:48.490 And specifically, the pricing of its essential 00:26:48.490 --> 00:26:50.930 test cartridges. These are the cartridges that 00:26:50.930 --> 00:26:53.450 are critical for rapidly detecting diseases like 00:26:53.450 --> 00:26:57.309 COVID -19, HIV, and most notably, tuberculosis, 00:26:57.609 --> 00:27:00.710 TB. The core conflict here is the tension between 00:27:00.710 --> 00:27:03.690 maximizing corporate profitability which has 00:27:03.690 --> 00:27:05.430 been the foundational principle of the Rails 00:27:05.430 --> 00:27:07.869 Brothers strategy from the start and ensuring 00:27:07.869 --> 00:27:10.089 global public health accessibility. Especially 00:27:10.089 --> 00:27:12.170 in low -income, high -disease burden countries 00:27:12.170 --> 00:27:14.670 where these diagnostics are most needed. Exactly. 00:27:14.690 --> 00:27:17.150 And organizations dedicated to global health, 00:27:17.250 --> 00:27:19.170 particularly the Treatment Action Group and Doctors 00:27:19.170 --> 00:27:21.630 Without Borders, have been very persistent critics. 00:27:21.869 --> 00:27:24.509 They've been publicly pressuring Cepheid to lower 00:27:24.509 --> 00:27:27.369 the prices of these tests since 2019. And what's 00:27:27.369 --> 00:27:29.769 their argument? They argue that the prices are 00:27:29.769 --> 00:27:32.130 unconscionable given the immense public health 00:27:32.130 --> 00:27:34.529 need and what they claim is the relatively low 00:27:34.529 --> 00:27:36.869 manufacturing cost. So the argument from the 00:27:36.869 --> 00:27:40.210 advocates is pretty stark. The expert MTBRF test, 00:27:40.450 --> 00:27:44.130 which detects TB, was being sold for $9 .98 per 00:27:44.130 --> 00:27:46.609 cartridge. Correct. And advocates argue that 00:27:46.609 --> 00:27:48.710 the true cost of manufacturing these cartridges, 00:27:48.970 --> 00:27:51.750 including all the materials and labor, is estimated 00:27:51.750 --> 00:27:55.089 to be closer to $3 or even less. So that disparity 00:27:55.089 --> 00:27:58.670 suggests profit margins that feel excessive when 00:27:58.670 --> 00:28:00.369 you're dealing with an essential life -saving 00:28:00.369 --> 00:28:02.410 tool in countries that lack public funding for 00:28:02.410 --> 00:28:05.049 universal health access. And this became a highly 00:28:05.049 --> 00:28:08.829 visible, very public dispute. When a major cultural 00:28:08.829 --> 00:28:12.430 figure, the author and vlogger John Green, intervened. 00:28:12.430 --> 00:28:15.410 Right. In September 2023, he released a video 00:28:15.410 --> 00:28:17.589 specifically highlighting these ethical concerns. 00:28:17.890 --> 00:28:20.529 And he used his platform to mobilize his massive 00:28:20.529 --> 00:28:22.809 online community to contact Danaher directly. 00:28:23.230 --> 00:28:26.329 That video drew unprecedented public scrutiny 00:28:26.329 --> 00:28:29.289 to this usually very quiet corporation. And the 00:28:29.289 --> 00:28:30.970 power of that public pressure was, I mean, it 00:28:30.970 --> 00:28:33.940 was undeniable. It was. One week after Green's 00:28:33.940 --> 00:28:36.960 video went viral, Danaher and Cepheid announced 00:28:36.960 --> 00:28:40.220 a specific, measurable action. They committed 00:28:40.220 --> 00:28:43.579 to a 20 % price reduction for the expert MTBRF 00:28:43.579 --> 00:28:46.200 TV test cartridge. And that decision dropped 00:28:46.200 --> 00:28:50.099 the price from $9 .98 to $7 .97 per cartridge, 00:28:50.299 --> 00:28:53.200 specifically applicable in high TV burden countries. 00:28:53.599 --> 00:28:56.140 Advocates celebrated this as a significant step. 00:28:56.589 --> 00:28:58.609 They acknowledged that corporate action had been 00:28:58.609 --> 00:29:01.089 compelled by public pressure. However, the response 00:29:01.089 --> 00:29:03.730 came with a crucial caveat that really complicates 00:29:03.730 --> 00:29:05.470 the victory and highlights the company's continuing 00:29:05.470 --> 00:29:07.630 balance of interests. A very important caveat. 00:29:07.829 --> 00:29:10.950 While the primary TB test price dropped. The 00:29:10.950 --> 00:29:13.769 price for the expert MTB -XDR test, which is 00:29:13.769 --> 00:29:15.970 the specialized test used to diagnose drug -resistant 00:29:15.970 --> 00:29:18.549 TB. The forum considered the deadliest and most 00:29:18.549 --> 00:29:20.970 complicated to treat. That price remained unchanged 00:29:20.970 --> 00:29:24.269 at $14 .90. So if we look at the implications, 00:29:24.509 --> 00:29:26.529 it tells us that Danaher conceded on the highest 00:29:26.529 --> 00:29:29.170 volume test, where the public criticism was loudest. 00:29:29.329 --> 00:29:31.329 But maintained the high profit margin on the 00:29:31.329 --> 00:29:34.269 most medically critical and complex test, the 00:29:34.269 --> 00:29:37.700 one for drug -resistant TB. Advocates argue this 00:29:37.700 --> 00:29:40.559 is proof that the strategy remains focused primarily 00:29:40.559 --> 00:29:43.740 on profit maximization, even if it requires a 00:29:43.740 --> 00:29:46.720 slight PR concession. This event really provides 00:29:46.720 --> 00:29:49.740 a perfect snapshot of the implications of Danaher's 00:29:49.740 --> 00:29:52.900 successful strategy. They have successfully acquired 00:29:52.900 --> 00:29:55.259 and consolidated technologies that are vital 00:29:55.259 --> 00:29:58.539 for global disease management, using DBS to achieve 00:29:58.539 --> 00:30:01.539 maximum operational efficiency. And the success 00:30:01.539 --> 00:30:03.839 of their focus strategy means they hold considerable 00:30:03.839 --> 00:30:06.619 influence over who gets access to these life 00:30:06.619 --> 00:30:09.559 -saving tools and at what cost. This constant 00:30:09.559 --> 00:30:11.980 tension between maximizing shareholder returns 00:30:11.980 --> 00:30:14.319 and ensuring global public health accessibility 00:30:14.319 --> 00:30:16.980 for critical diagnostic tools will undoubtedly 00:30:16.980 --> 00:30:19.299 continue to define their ethical footprint as 00:30:19.299 --> 00:30:21.220 they deepen their control over the health care 00:30:21.220 --> 00:30:23.279 supply chain. It raises an important question 00:30:23.279 --> 00:30:25.759 for all of us. When you are manufacturing the 00:30:25.759 --> 00:30:28.119 core defenses against pandemics and fatal diseases, 00:30:28.380 --> 00:30:30.759 does the traditional corporate model of profit 00:30:30.759 --> 00:30:33.440 maximization still hold up? Or does the critical 00:30:33.440 --> 00:30:35.339 nature of the product demand a different global 00:30:35.339 --> 00:30:37.700 pricing structure? What we have tracked today 00:30:37.700 --> 00:30:40.180 is more than just a corporate history. It is 00:30:40.180 --> 00:30:42.819 a textbook case study in corporate reinvention, 00:30:42.980 --> 00:30:46.420 driven by ruthless strategic clarity and operational 00:30:46.420 --> 00:30:50.119 excellence. Danaher Corporation is the ultimate 00:30:50.119 --> 00:30:53.019 example of a highly curated, rapidly evolving 00:30:53.019 --> 00:30:55.400 conglomerate. That identity is fundamentally 00:30:55.400 --> 00:30:58.180 defined by the constant, intentional process 00:30:58.180 --> 00:31:01.849 dictated by the Danaher business system. It's 00:31:01.849 --> 00:31:04.650 a process of acquisition buying knowledge, technical 00:31:04.650 --> 00:31:07.369 scale and market share, followed by the simultaneous 00:31:07.369 --> 00:31:10.210 spinoff shedding complexity, shedding capital 00:31:10.210 --> 00:31:12.730 and shedding any assets that are not immediately 00:31:12.730 --> 00:31:15.490 core to the highest growth, highest margin scientific 00:31:15.490 --> 00:31:18.190 and health care verticals. Yeah, they systematically 00:31:18.190 --> 00:31:20.890 stripped away tools, dental equipment, environmental 00:31:20.890 --> 00:31:23.789 testing businesses, becoming almost purely a 00:31:23.789 --> 00:31:26.049 health care company supplying the absolute essentials. 00:31:26.170 --> 00:31:28.869 And the results are undeniable. They're a massive 00:31:28.869 --> 00:31:40.660 Fortune 500 company. and the advanced molecular 00:31:40.660 --> 00:31:43.359 diagnostics from Cepheid. The discussion surrounding 00:31:43.359 --> 00:31:46.420 the Cepheid controversy highlights that the company's 00:31:46.420 --> 00:31:48.599 success places it at the center of the largest 00:31:48.599 --> 00:31:51.940 ethical debates of our time. Their intense focus 00:31:51.940 --> 00:31:55.640 on vital, lifesaving technology, technology that 00:31:55.640 --> 00:31:58.119 literally determines who gets access to rapid 00:31:58.119 --> 00:32:01.059 diagnosis in disease -prone regions, inevitably 00:32:01.059 --> 00:32:03.740 increases the scrutiny on their ethical responsibility 00:32:03.740 --> 00:32:07.039 regarding global accessibility and pricing. Absolutely. 00:32:07.559 --> 00:32:10.339 Just thinking about the scale and audacity required 00:32:10.339 --> 00:32:14.799 to manage 63 ,000 people and spin off $30 billion 00:32:14.799 --> 00:32:18.579 worth of companies in a single decade, all while 00:32:18.579 --> 00:32:20.940 flawlessly integrating multi -billion dollar 00:32:20.940 --> 00:32:23.599 acquisitions. I mean, that demonstrates a level 00:32:23.599 --> 00:32:25.700 of strategic discipline most companies can only 00:32:25.700 --> 00:32:28.000 dream of. But with that unparalleled discipline 00:32:28.000 --> 00:32:30.640 and market control comes an elevated moral burden. 00:32:30.900 --> 00:32:33.359 So here is a final provocative thought for you 00:32:33.359 --> 00:32:35.990 to consider. Danaher's entire history has been 00:32:35.990 --> 00:32:38.230 defined by the principle of maximizing efficiency 00:32:38.230 --> 00:32:40.650 and financial focus through the Danaher business 00:32:40.650 --> 00:32:43.230 system. Now that they have successfully concentrated 00:32:43.230 --> 00:32:45.210 almost all their energy into the most critical 00:32:45.210 --> 00:32:47.829 lifesaving sectors of the global economy, does 00:32:47.829 --> 00:32:50.529 their sheer success necessitate a new strategic 00:32:50.529 --> 00:32:53.410 calculation? A calculation where accessibility 00:32:53.410 --> 00:32:56.230 for critical goods must be factored in alongside 00:32:56.230 --> 00:32:58.869 the traditional measures of corporate efficiency 00:32:58.869 --> 00:33:02.049 and profit. Are they too big and too important 00:33:02.049 --> 00:33:04.250 for their strategy to be only about the bottom 00:33:04.250 --> 00:33:06.789 line? It's a tension that every shareholder, 00:33:06.970 --> 00:33:09.630 every patient, and every public health advocate 00:33:09.630 --> 00:33:12.890 must keep an eye on as Danaher continues to supply 00:33:12.890 --> 00:33:16.109 the very essence of human medical defense. Thank 00:33:16.109 --> 00:33:18.369 you for joining us for this deep dive into the 00:33:18.369 --> 00:33:20.390 quiet powerhouse that is Danaher Corporation. 00:33:20.829 --> 00:33:21.430 We'll see you next time.